Fluticasone Propionate And Salmeterol Powder
Product Images NDC 70518-4347

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Fluticasone Propionate And Salmeterol (NDC 70518-4347). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Fluticasone Propionate and Salmeterol Inhalation Powder 250 mcg / 50 mcg in a package of 60 blisters. The label indicates it is for oral inhalation only and is repackaged by RemedyRepack Inc., Indiana, PA. Storage instructions advise keeping the product away from direct heat or sunlight and temperature control at 20-25°C with permitted excursions.*

FDA Label Image

Fluticasone Propionate Chemical Structure (Fp Sal Spl Graphic 01)

Chemical structure depicting the active ingredients fluticasone propionate and salmeterol, shown as a detailed molecular diagram with atomic bonds and groups typical of these respiratory inhalation agents.*

FDA Label Image

Salmeterol Xinafoate Chemical Structure (Fp Sal Spl Graphic 02)

Chemical structure of the active ingredients fluticasone propionate and salmeterol, shown as two distinct molecular formulas connected by their typical chemical groups.*

FDA Label Image

Figure 1. Mean Percent Change From Baseline In Fev1 In Subjects With Asthma Previously Treated With Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 03)

A line graph showing the percentage change in FEV1 over 12 weeks for four groups: Fluticasone propionate/salmeterol 100/50 mcg twice daily, Fluticasone propionate 100 mcg twice daily, Salmeterol 50 mcg twice daily, and Placebo. The graph illustrates higher FEV1 improvements in combination therapy compared to individual components and placebo, with patient numbers listed for each group at weeks 0, 6, 12, and endpoint.*

FDA Label Image

Figure 2. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 04)

Line graph depicting the percentage change in FEV1 over 12 hours post-baseline on Day 1 for four groups: Fluticasone propionate/salmeterol 100/50 mcg twice daily, Salmeterol 50 mcg twice daily, Fluticasone propionate 100 mcg twice daily, and placebo. The chart tracks respiratory function changes (FEV1) across participants in each treatment group.*

FDA Label Image

Figure 3. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 05)

A line graph showing the percentage change in FEV1 relative to Day 1 baseline over 12 hours. The chart compares four groups: fluticasone propionate/salmeterol 100/50 mcg twice daily, salmeterol 50 mcg twice daily, fluticasone propionate 100 mcg twice daily, and placebo. The graph illustrates differences in lung function response over time with the combination therapy showing the greatest improvement.*

FDA Label Image

Figure 4. Predose Fev1: Mean Percent Change From Baseline In Subjects With Chronic Obstructive Pulmonary Disease (Fp Sal Spl Graphic 06)

A line graph showing percentage change in FEV1 (lung function) over 24 weeks among three groups: Fluticasone propionate/salmeterol DISKUS 250/50 mcg, Salmeterol 50 mcg, and Placebo. The graph includes sample sizes for each group at multiple time points throughout the study period.*

FDA Label Image

Figure 5. Two-hour Postdose Fev1: Mean Percent Changes From Baseline Over Time In Subjects With Chronic Obstructive Pulmonary Disease (Fp Sal Spl Graphic 07)

A line graph showing percent change in FEV1 over time for three groups: fluticasone propionate/salmeterol 250/50 mcg twice daily, fluticasone propionate 250 mcg twice daily, and placebo. The x-axis shows time from Day 1 to Week 24. The fluticasone propionate/salmeterol group shows the greatest improvement in FEV1 percent change, followed by fluticasone propionate alone, while placebo shows the least change. Sample sizes are listed below the graph for each group at different time points.*

FDA Label Image

Figure A (Fp Sal Spl Graphic 08)

Illustration of the Fluticasone Propionate and Salmeterol DISKUS inhaler device showing labeled parts including the outer case, mouthpiece, lever, thumb grip, and dose counter. The label on the DISKUS indicates a powder inhalation product with 100 mcg fluticasone propionate and 50 mcg salmeterol dosage strength.*

FDA Label Image

Figure B (Fp Sal Spl Graphic 09)

An instructional image showing hands holding a Fluticasone Propionate and Salmeterol DISKUS inhaler. The image illustrates the action of sliding the inhaler cover open, indicated by a large arrow pointing to the right, demonstrating how to prepare the device for use.*

FDA Label Image

Figure C (Fp Sal Spl Graphic 10)

An instructional illustration showing a person holding a Fluticasone Propionate and Salmeterol DISKUS inhalation device. The image highlights the proper hand positioning and includes an arrow indicating the direction in which the device should be opened or pushed to prepare for inhalation.*

FDA Label Image

Figure D (Fp Sal Spl Graphic 11)

An instructional illustration showing a woman using a respiratory inhaler device, demonstrating proper inhalation technique by holding the device near her mouth while exhaling or preparing to inhale the powder medication.*

FDA Label Image

Figure E (Fp Sal Spl Graphic 12)

Black and white illustration of a woman using a handheld inhaler device, demonstrating the correct method of inhalation. The image focuses on respiratory administration technique, relevant to inhaled powder medications like Fluticasone Propionate and Salmeterol DISKUS.*

FDA Label Image

Figure F (Fp Sal Spl Graphic 13)

Instructional illustration showing hands holding a Fluticasone Propionate and Salmeterol DISKUS inhaler with an arrow indicating the direction to slide the lever, demonstrating how to prepare the inhaler for use.*

FDA Label Image

Figure G (Fp Sal Spl Graphic 14)

An instructional grayscale illustration showing a woman using a spit technique by leaning over a sink and expelling saliva. A glass of water is placed nearby on the countertop. No product packaging or labeling is visible in the image.*

FDA Label Image

Figure H (Fp Sal Spl Graphic 15)

Fluticasone Propionate and Salmeterol DISKUS inhalation powder 100 mcg/50 mcg powder in a black and gray shaped blister disk containing 60 inhalations. The device is labeled with strength and instructions to record pouch opening and use-by dates. The product is by RemedyRepack Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.